Supplier
Neshoba County General Hospital
Neshoba County General Hospital was paid $22.43M by Medicaid between Jan 2018 and Dec 2024, across 183 billing codes. Its largest line is 99283, emergency room visit (moderate) — 23% of everything it billed.
33Billing provider infoNESHOBA COUNTY GENERAL HOSPITAL
PHILADELPHIA, MS 39350
PHILADELPHIA, MS 39350
33aNPI1083659734assigned 06/18/2006
33bProvider typeLong Term Care Pharmacy
28Total paid$22.43M
24GClaims700,796
24DCodes billed183
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Long Term Care Pharmacy providers in Mississippi
Rank by total paid#1 of 6
Median peer was paid$0.00
This provider vs. median0.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 107,991 | $2.85M | |
| 2019 | 88,272 | $3.08M | |
| 2020 | 74,031 | $2.40M | |
| 2021 | 95,595 | $3.32M | |
| 2022 | 123,899 | $4.04M | |
| 2023 | 113,557 | $3.76M | |
| 2024incomplete | 97,451 | $2.97M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 37,906 | 30,407 | $5.19M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 17,016 | 13,967 | $3.10M |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 5.4% | 99,695 | 39,949 | $1.22M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 5.4% | 37,011 | 30,971 | $1.21M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.2% | 5,820 | 4,806 | $1.16M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.8% | 21,407 | 17,259 | $843K |
| G0378 | Hospital observation service, per hour | 3.2% | 1,754 | 1,372 | $721K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3.2% | 59,614 | 47,647 | $716K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.8% | 16,833 | 3,589 | $626K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 7,114 | 5,852 | $574K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 2.5% | 6,254 | 3,746 | $560K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.3% | 6,793 | 5,402 | $522K |
171 more codes
| 71046 | Radiologic examination, chest; 2 views | 2.0% | 10,719 | $449K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.8% | 8,226 | $395K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 1.6% | 3,611 | $366K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 3,925 | $335K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.5% | 1,826 | $329K |
| 71045 | Radiologic examination, chest; single view | 1.4% | 8,707 | $313K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.1% | 6,085 | $239K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 4,091 | $194K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,142 | $193K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 34,840 | $186K |
| 87807 | <1% | 17,250 | $182K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 5,919 | $169K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,261 | $169K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,863 | $161K |
| 74018 | <1% | 3,546 | $158K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,291 | $153K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,823 | $147K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,381 | $105K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 3,608 | $102K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 17,671 | $98K |
| 97161 | <1% | 1,948 | $88K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 33,566 | $87K |
| 83880 | <1% | 3,719 | $64K | |
| 73610 | <1% | 1,414 | $60K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,932 | $52K |
| 83655 | <1% | 4,850 | $52K | |
| 80061 | Lipid panel | <1% | 5,291 | $50K |
| 80076 | <1% | 9,248 | $49K | |
| 80047 | <1% | 5,793 | $47K | |
| 80053 | Comprehensive metabolic panel | <1% | 5,686 | $43K |
| 73630 | <1% | 825 | $39K | |
| 73030 | <1% | 1,059 | $37K | |
| 84484 | <1% | 5,936 | $35K | |
| 81001 | <1% | 16,639 | $35K | |
| 81025 | <1% | 5,791 | $35K | |
| 73130 | <1% | 759 | $34K | |
| 80305 | <1% | 4,531 | $32K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,879 | $32K |
| 73560 | <1% | 900 | $30K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 423 | $29K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 646 | $26K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,901 | $25K |
| 73620 | <1% | 776 | $25K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,363 | $25K |
| 72100 | <1% | 478 | $24K | |
| 83735 | <1% | 5,639 | $20K | |
| 87040 | <1% | 2,969 | $20K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,380 | $20K |
| 83874 | <1% | 2,768 | $17K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,007 | $17K |
| 64483 | <1% | 88 | $17K | |
| 97016 | <1% | 2,389 | $16K | |
| 97116 | <1% | 942 | $16K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 284 | $16K |
| 73100 | <1% | 374 | $16K | |
| 73562 | <1% | 377 | $15K | |
| 82553 | <1% | 2,571 | $15K | |
| 83690 | <1% | 3,225 | $14K | |
| 92523 | <1% | 94 | $13K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 93 | $13K |
| 82962 | <1% | 7,666 | $13K | |
| 82550 | <1% | 3,512 | $13K | |
| 64493 | <1% | 29 | $13K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 261 | $10K |
| 84439 | <1% | 1,497 | $10K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 55 | $10K |
| 83605 | <1% | 1,740 | $10K | |
| 85730 | <1% | 3,155 | $10K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 399 | $9K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 230 | $9K |
| 72110 | <1% | 182 | $9K | |
| 85610 | <1% | 3,630 | $8K | |
| 97533 | <1% | 248 | $8K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 295 | $7K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 276 | $7K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 99 | $6K |
| 73502 | <1% | 196 | $5K | |
| 87210 | <1% | 1,548 | $5K | |
| 97597 | <1% | 99 | $5K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 87 | $4K |
| 97113 | <1% | 62 | $4K | |
| 85379 | <1% | 735 | $4K | |
| 86140 | <1% | 1,025 | $4K | |
| 82607 | <1% | 419 | $3K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 56 | $3K |
| 87081 | <1% | 550 | $3K | |
| 73070 | <1% | 55 | $3K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 13 | $3K |
| 87088 | <1% | 400 | $3K | |
| 73090 | <1% | 63 | $2K | |
| 73590 | <1% | 44 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,042 | $2K |
| 82728 | <1% | 279 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 228 | $2K |
| 72040 | <1% | 48 | $2K | |
| 82746 | <1% | 232 | $2K | |
| 87186 | <1% | 248 | $2K | |
| 87077 | <1% | 256 | $2K | |
| 95816 | <1% | 19 | $1K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 14 | $1K |
| 87581 | <1% | 92 | $1K | |
| 72070 | <1% | 15 | $1K | |
| 96367 | <1% | 23 | $1K | |
| 82248 | <1% | 268 | $1K | |
| 85651 | <1% | 398 | $924.59 | |
| 84207 | <1% | 65 | $758.70 | |
| 87070 | <1% | 101 | $735.74 | |
| 82805 | <1% | 20 | $708.90 | |
| 73140 | <1% | 12 | $630.76 | |
| 70220 | <1% | 24 | $598.74 | |
| 84425 | <1% | 66 | $592.41 | |
| 86318 | <1% | 45 | $577.00 | |
| 82247 | <1% | 158 | $538.91 | |
| 86592 | <1% | 157 | $483.62 | |
| 84702 | <1% | 42 | $483.35 | |
| 82150 | <1% | 99 | $407.57 | |
| 80177 | <1% | 57 | $372.48 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 14 | $367.72 |
| 86580 | <1% | 102 | $363.83 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,230 | $287.00 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 12 | $216.72 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,256 | $194.24 |
| 83540 | <1% | 52 | $192.34 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,444 | $188.95 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,685 | $168.93 |
| 84481 | <1% | 22 | $167.75 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,475 | $165.06 |
| 86308 | <1% | 39 | $161.05 | |
| 86618 | <1% | 18 | $137.97 | |
| 85018 | <1% | 58 | $136.01 | |
| 82043 | <1% | 47 | $134.92 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,790 | $129.75 |
| 84446 | <1% | 20 | $114.84 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 24 | $83.50 |
| J3490 | Unclassified drugs | <1% | 3,504 | $83.37 |
| 83550 | <1% | 15 | $76.08 | |
| 83721 | <1% | 15 | $68.32 | |
| 82465 | <1% | 13 | $42.42 | |
| 82565 | <1% | 15 | $36.88 | |
| 84520 | <1% | 14 | $28.48 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 105 | $26.46 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 304 | $24.23 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,679 | $23.70 |
| G0306 | Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count | <1% | 1,131 | $18.98 |
| 83615 | <1% | 14 | $16.34 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 203 | $4.59 |
| 80050 | General health panel | <1% | 1,710 | $3.37 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 53 | $2.16 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 217 | $1.84 |
| 96376 | <1% | 543 | $1.06 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 22 | $0.96 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 1,867 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 534 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 159 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 119 | $0.00 |
| A4248 | Chlorhexidine containing antiseptic, 1 ml | 0% | 42 | $0.00 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 41 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 14 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 1,973 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 188 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 784 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 12 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 187 | $0.00 |
| 94760 | 0% | 593 | $0.00 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 28 | $0.00 |
| 64494 | 0% | 29 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 21 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 100 | $0.00 |
| 64484 | 0% | 41 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 14 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCALL, GARY (CEO)
| Provider | Location | Paid |
|---|---|---|
| Neshoba County General Hospital | Philadelphia, MS | $7.24M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.